Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIDWELL-D3 is a branded generic formulation of cholecalciferol (vitamin D3) developed and marketed by Wellmed Pharma. It is presented as a 'Nano Shot' containing 60,000 IU of cholecalciferol, a small molecule that acts as a precursor to the active form of vitamin D. Cholecalciferol is essential for the regulation of calcium and phosphate levels in the body, primarily by binding to and activating the Vitamin D receptor (VDR) in the intestines and bones. This activation enhances intestinal calcium absorption and supports bone mineralization. AIDWELL-D3 is used for the treatment and prevention of vitamin D deficiency and to support overall bone health, particularly in conditions like osteoporosis and osteomalacia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AIDWELL-D3.